Blinatumomab: new antibody treatment for acute lymphocytic leukaemia

Blincyto (blinatumomab) is licensed for the treatment of adults with Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukaemia.

Further information
View Blincyto drug record 
Summary of Product Characteristics
Manufacturer: Amgen

The antibody is a bispecific T-cell engager that binds to CD19 on the surface of cells in B-lineage origin and CD3 expressed on the surface of T-cells. Blinatumomab activates endogenous T-cells by connecting to CD3 in the T-cell receptor complex with CD19 on benign and malignant B-cells. The formation of a cytolytic synapse between the T-cell and the tumour cell causes the release of proteolytic enzymes, which kills both proliferating and resting target cells.

Patients may receive 2 cycles of treatment. A single cycle of treatment is 4 weeks of continuous infusion. followed by a 2-week treatment-free interval. Patients who have achieved complete remission after 2 treatment cycles may receive up to 3 additional cycles of blinatumomab treatment, based on an individual risk-benefit assessment.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Compare COVID-19 vaccines with new MIMS table

Compare COVID-19 vaccines with new MIMS table

Key characteristics of available COVID-19 vaccines...

Deleted products - live tracker

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...